Literature DB >> 21933221

Isolated growth hormone deficiency in two siblings because of paternal mosaicism for a mutation in the GH1 gene.

Mayuko Tsubahara1, Yoshitaka Hayashi, Shin-ichi Niijima, Michiyo Yamamoto, Takashi Kamijo, Yoshiharu Murata, Hidenori Haruna, Akihisa Okumura, Toshiaki Shimizu.   

Abstract

CONTEXT: Mutations in the GH1 gene have been identified in patients with isolated growth hormone deficiency (IGHD). Mutations causing aberrant splicing of exon 3 of GH1 that have been identified in IGHD are inherited in an autosomal dominant manner, whereas other mutations in GH1 that have been identified in IGHD are inherited in an autosomal recessive manner.
OBJECTIVE: Two siblings born from nonconsanguineous healthy parents exhibited IGHD. To elucidate the cause, GH1 in all family members was analysed.
RESULTS: Two novel mutations in GH1, a point mutation in intron 3 and a 16-bp deletion in exon 3, were identified by sequence analyses. The intronic mutation was present in both siblings and was predicted to cause aberrant splicing. The deletion was present in one of the siblings as well as the mother with normal stature and was predicted to cause rapid degradation of mRNA through nonsense-mediated mRNA decay. The point mutation was not identified in the parents' peripheral blood DNA; however, it was detected in the DNA extracted from the father's sperms. As a trace of the mutant allele was detected in the peripheral blood of the father using PCR-RFLP, the mutation is likely to have occurred de novo at an early developmental stage before differentiation of somatic cells and germline cells.
CONCLUSIONS: This is the first report of mosaicism for a mutation in GH1 in a family with IGHD. It is clear that the intronic mutation plays a dominant role in the pathogenesis of IGHD in this family, as one of the siblings who had only the point mutation was affected. On the other hand, the other sibling was a compound heterozygote for the point mutation and the 16-bp deletion and it may be arguable whether IGHD in this patient should be regarded as autosomal dominant or recessive.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21933221     DOI: 10.1111/j.1365-2265.2011.04224.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  1 in total

1.  Assessment of copy number variations in the brain genome of schizophrenia patients.

Authors:  Miwako Sakai; Yuichiro Watanabe; Toshiyuki Someya; Kazuaki Araki; Masako Shibuya; Kazuhiro Niizato; Kenichi Oshima; Yasuto Kunii; Hirooki Yabe; Junya Matsumoto; Akira Wada; Mizuki Hino; Takeshi Hashimoto; Akitoyo Hishimoto; Noboru Kitamura; Shuji Iritani; Osamu Shirakawa; Kiyoshi Maeda; Akinori Miyashita; Shin-Ichi Niwa; Hitoshi Takahashi; Akiyoshi Kakita; Ryozo Kuwano; Hiroyuki Nawa
Journal:  Mol Cytogenet       Date:  2015-07-01       Impact factor: 2.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.